Ovid Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Ovid Therapeutics

13/05/2025 14:31

Ovid Therapeutics Inc OVID.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -17 cents.  The mean expectation of seven analysts for the quarter was for a loss of 14 cents per share. Wall Street expected results to range from -15 cents to -13 cents per share.

Revenue fell 12.2% to $130.00 thousand from a year ago; analysts expected $50.00 thousand.

Ovid Therapeutics Inc's reported EPS for the quarter was a loss of 14 cents​.

The company reported a quarterly loss of $10.24 million.

Ovid Therapeutics Inc shares had fallen by 3.2% this quarter and lost 67.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 5.1% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Ovid Therapeutics Inc is $3.00

This summary was machine generated from LSEG data May 13 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.14
-0.14
Met
Dec. 31 2024
-0.17
-0.13
Beat
Sep. 30 2024
-0.20
-0.20
Met
Jun. 30 2024
-0.22
0.12
Beat